Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Shlomit S. Shachar; Michelle Leviov; Rinat Yerushalmi; Karen Drumea; Margarita Tokar; Lior Soussan-Gutman; Avital Bareket-Samish; Amir Sonnenblick; Noa Ben-Baruch; Ella Evron; Einav Nili Gal-Yam; Shani Paluch-Shimon; Gil Bar-Sela; Hadar Goldvaser; Salomon M. Stemmer

doi:10.1038/s41523-023-00586-3

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Shlomit S. Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Ben-Baruch, Ella Evron, Einav Nili Gal-Yam, Shani Paluch-Shimon, Gil Bar-Sela, Hadar Goldvaser, Salomon M. Stemmer

Tel Aviv University, Ben-Gurion University of the Negev, Technion - Israel Institute of Technology

Research output: Contribution to journal › Article › peer-review

Abstract

Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a ‘study-cohort’ (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a ‘general 21-gene-tested BC-cohort’ (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the ‘study-cohort’ were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.

Original language	English
Article number	79
Pages (from-to)	79
Journal	NPJ Breast Cancer
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41523-023-00586-3
State	Published - 1 Dec 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

Access to Document

10.1038/s41523-023-00586-3

Cite this

Shachar, S. S., Leviov, M., Yerushalmi, R., Drumea, K., Tokar, M., Soussan-Gutman, L., Bareket-Samish, A., Sonnenblick, A., Ben-Baruch, N., Evron, E., Gal-Yam, E. N., Paluch-Shimon, S., Bar-Sela, G., Goldvaser, H., & Stemmer, S. M. (2023). Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry. NPJ Breast Cancer, 9(1), 79. Article 79. https://doi.org/10.1038/s41523-023-00586-3

@article{1234ccf9ad4141288f900d8b62c809cc,

title = "Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry",

abstract = "Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a {\textquoteleft}study-cohort{\textquoteright} (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a {\textquoteleft}general 21-gene-tested BC-cohort{\textquoteright} (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68\%. Patient/tumor characteristics of the first- and second-BC in the {\textquoteleft}study-cohort{\textquoteright} were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.",

author = "Shachar, \{Shlomit S.\} and Michelle Leviov and Rinat Yerushalmi and Karen Drumea and Margarita Tokar and Lior Soussan-Gutman and Avital Bareket-Samish and Amir Sonnenblick and Noa Ben-Baruch and Ella Evron and Gal-Yam, \{Einav Nili\} and Shani Paluch-Shimon and Gil Bar-Sela and Hadar Goldvaser and Stemmer, \{Salomon M.\}",

note = "Publisher Copyright: {\textcopyright} 2023, Springer Nature Limited.",

year = "2023",

month = dec,

day = "1",

doi = "10.1038/s41523-023-00586-3",

language = "الإنجليزيّة",

volume = "9",

pages = "79",

journal = "NPJ Breast Cancer",

issn = "2374-4677",

publisher = "Nature Publishing Group",

number = "1",

}

Shachar, SS, Leviov, M, Yerushalmi, R, Drumea, K, Tokar, M, Soussan-Gutman, L, Bareket-Samish, A, Sonnenblick, A, Ben-Baruch, N, Evron, E, Gal-Yam, EN, Paluch-Shimon, S, Bar-Sela, G, Goldvaser, H & Stemmer, SM 2023, 'Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry', NPJ Breast Cancer, vol. 9, no. 1, 79, pp. 79. https://doi.org/10.1038/s41523-023-00586-3

TY - JOUR

T1 - Second breast cancer

T2 - recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

AU - Shachar, Shlomit S.

AU - Leviov, Michelle

AU - Yerushalmi, Rinat

AU - Drumea, Karen

AU - Tokar, Margarita

AU - Soussan-Gutman, Lior

AU - Bareket-Samish, Avital

AU - Sonnenblick, Amir

AU - Ben-Baruch, Noa

AU - Evron, Ella

AU - Gal-Yam, Einav Nili

AU - Paluch-Shimon, Shani

AU - Bar-Sela, Gil

AU - Goldvaser, Hadar

AU - Stemmer, Salomon M.

PY - 2023/12/1

Y1 - 2023/12/1

N2 - Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a ‘study-cohort’ (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a ‘general 21-gene-tested BC-cohort’ (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the ‘study-cohort’ were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.

AB - Data on using the 21-gene Recurrence Score (RS) testing on second breast cancer (BC; second primary or local recurrence) are lacking. This cohort study examined patients with first and second BC, who underwent 21-gene testing both times. It included a ‘study-cohort’ (60 N0/N1mi/N1 ER + HER2‒ BC patients with ≥2 RS results >1 year apart) and a ‘general 21-gene-tested BC-cohort’ (2044 previously described N0/N1mi/N1 patients). The median time between the first and second BC was 5.2 (IQR, 3.1–7.1) years; the second BC was ipsilateral in 68%. Patient/tumor characteristics of the first- and second-BC in the ‘study-cohort’ were similar, except for the RS which was higher in the second BC (median [IQR]: 23 [17–30] vs 17 [14–22], p < 0.001). Overall, 56 patients had follow-up data, of whom 5 experienced distant recurrence (2 RS 11–25 patients and 3 RS 26–100 patients). Studies exploring the prognostic utility of the RS in this setting are warranted.

UR - http://www.scopus.com/inward/record.url?scp=85173977510&partnerID=8YFLogxK

U2 - 10.1038/s41523-023-00586-3

DO - 10.1038/s41523-023-00586-3

M3 - مقالة

C2 - 37775723

SN - 2374-4677

VL - 9

SP - 79

JO - NPJ Breast Cancer

JF - NPJ Breast Cancer

IS - 1

M1 - 79

ER -

Second breast cancer: recurrence score results, clinicopathologic characteristics, adjuvant treatments, and outcomes—exploratory analysis of the Clalit registry

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this